Literature DB >> 18202406

mTOR: the mammalian target of replication.

Ezra E W Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18202406     DOI： 10.1200/JCO.2007.14.3164

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Ruta graveolens extract induces DNA damage pathways and blocks Akt activation to inhibit cancer cell proliferation and survival.

Authors:  Khalda Fadlalla; Angela Watson; Teshome Yehualaeshet; Timothy Turner; Temesgen Samuel
Journal:  Anticancer Res       Date:  2011-01       Impact factor: 2.480

2.  Rapamycin, anti-aging, and avoiding the fate of Tithonus.

Authors:  Arlan Richardson
Journal:  J Clin Invest       Date:  2013-08       Impact factor: 14.808

3.  Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.

Authors:  Tara C Gangadhar; Ezra E W Cohen; Kehua Wu; Linda Janisch; David Geary; Masha Kocherginsky; Larry K House; Jackie Ramirez; Samir D Undevia; Michael L Maitland; Gini F Fleming; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

4.  A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.

Authors:  E E W Cohen; M R Sharma; L Janisch; M Llobrera; L House; K Wu; J Ramirez; G F Fleming; W M Stadler; M J Ratain
Journal:  Eur J Cancer       Date:  2011-03-23       Impact factor: 9.162

5.  Current and emerging treatments for chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 6.  Effect of rapamycin on aging and age-related diseases-past and future.

Authors:  Ramasamy Selvarani; Sabira Mohammed; Arlan Richardson
Journal:  Geroscience       Date:  2020-10-10       Impact factor: 7.713

Review 7.  Role of LKB1 in lung cancer development.

Authors:  L Makowski; D N Hayes
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

Review 8.  Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.

Authors:  Athanasia Pavlidou; Nikos F Vlahos
Journal:  ScientificWorldJournal       Date:  2014-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.